<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03419897</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-208</org_study_id>
    <nct_id>NCT03419897</nct_id>
  </id_info>
  <brief_title>Study of BGB-A317 in Patients With Previously Treated Unresectable HCC</brief_title>
  <official_title>A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and
      Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients with Previously
      Treated Hepatocellular Unresectable Carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) assessed by Independent Review Committee (IRC)</measure>
    <time_frame>From date of enrollment up to 4 years, approximately</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From first determination of an objective response up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of enrollment up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From first dose of study treatment up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>From first dose of study treatment up to 4 years, approximately.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of enrollment up to 4 years, approximately.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with adverse events</measure>
    <time_frame>From date of enrollment up to 4 years, approximately.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL)</measure>
    <time_frame>At screening or baseline up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Signs Findings</measure>
    <time_frame>At screening or baseline up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Physical Examination Findings</measure>
    <time_frame>At screening or baseline up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Results Findings</measure>
    <time_frame>At screening or baseline up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings</measure>
    <time_frame>At screening or baseline up to 4 years, approximately</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>BGB-A317</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGB-A317: 200 mg once every 3 weeks (Q3W), intravenous dosing (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A317</intervention_name>
    <description>Anti-PD-1 ANTIBODY</description>
    <arm_group_label>BGB-A317</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed HCC

          2. Patients with Barcelona Clinic Liver Cancer (BCLC) Stage C, or BCLC stage B not
             amenable to locoregional therapy or relapsed after locoregional therapy, and not
             amenable to a curative treatment approach

          3. Has received at least 1 line of systemic therapy for unresectable HCC

          4. Has at least 1 measurable lesion as defined per RECIST v1.1

          5. Child-Pugh score A

          6. Easter Cooperative Oncology Group (ECOG) Performance Status â‰¤ 1

          7. Adequate organ function

        Exclusion Criteria:

          1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
             histology

          2. Prior therapies targeting PD-1 or PD-L1

          3. Has Known brain or leptomeningeal metastasis

          4. Tumor thrombus involving main trunk of portal vein or inferior vena cava

          5. Loco-regional therapy to the liver within 4 weeks before enrollment

          6. Medical history of interstitial lung disease, non-infectious pneumonitis or
             uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis,
             acute lung diseases, etc

          7. Has received:

               1. Within 28 days or 5 half-lives (whichever is shorter) of the first study drug
                  administration: any chemotherapy, immunotherapy (eg, interleukin, interferon,
                  thymoxin) or any investigational therapies

               2. Within 14 days of the first study drug administration: sorafenib, regorafenib, or
                  any Chinese herbal medicine or Chinese patent medicines used to control cancer

          8. Active autoimmune diseases or history of autoimmune diseases that may relapse

          9. Patient with any condition requiring systemic treatment with either corticosteroids (&gt;
             10 mg daily of prednisone or equivalent) or other immunosuppressive medication within
             14 days before study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeannie Hou, Senior Director</last_name>
    <phone>+14152978774</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy Li, Senior Director</last_name>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu Province, P.R.</state>
        <zip>221009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Liu</last_name>
    </contact>
    <investigator>
      <last_name>Yong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

